Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs risedronate for glucocorticoid-induced bone loss
KCT0011845Phase 4Not yet recruiting
- Sponsor
- Samsung Bioepis
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of denosumab in osteoporosis, glucocorticoid-induced osteoporosis (GIOP), sponsored by Samsung Bioepis. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisglucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on KCT0011845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011845.